EP Patent

EP3810084A1 — Pharmaceutical formulation of odevixibat

Assigned to Albireo AB · Expires 2021-04-28 · 5y expired

What this patent protects

The invention relates to a pharmaceutical formulation, e.g. a paediatric formulation,of odevixibat, which comprises a plurality of small particles. The formulation may be used in the treatment ofliver diseases such as bile acid-dependent liver diseases, and particularly cholestat…

USPTO Abstract

The invention relates to a pharmaceutical formulation, e.g. a paediatric formulation,of odevixibat, which comprises a plurality of small particles. The formulation may be used in the treatment ofliver diseases such as bile acid-dependent liver diseases, and particularly cholestatic liver diseases such as biliary atresia,progressive familial intrahepatic cholestasis (PFIC), Alagille syndrome (ALGS) and paediatric cholestatic pruritus. The invention also relates to a process for the preparation of the pharmaceutical formulation.

Drugs covered by this patent

Patent Metadata

Patent number
EP3810084A1
Jurisdiction
EP
Classification
—
Expires
2021-04-28
Drug substance claim
No
Drug product claim
No
Assignee
Albireo AB
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.